-
Earlier this month, McKesson Corporation announced that long‑time Chief Financial Officer Britt Vitalone will retire as CFO on May 28, 2026, with incoming Executive Vice President Kenny Cheung set to assume the finance leadership role from May 29, 2026, while Vitalone remains as a strategic advisor through the planned separation of Medical Surgical Solutions.
-
At the same time, McKesson’s progress in securing a new National Drug Code for a biosimilar version of Neulasta highlights how finance leadership transition is occurring alongside an expansion into more complex, higher‑value pharmaceutical offerings.
-
Now we’ll examine how McKesson’s biosimilar National Drug Code approval could shape its investment narrative around specialty growth and services.
Find 48 companies with promising cash flow potential yet trading below their fair value.
To own McKesson, you generally need to believe in steady prescription volume growth, expanding specialty and oncology services, and the company’s ability to handle regulatory and margin pressure. The new CFO appointment and biosimilar National Drug Code approval do not materially change the near term focus on specialty growth, but they sit alongside the ongoing risk that tighter drug pricing rules could pressure profitability.
The most relevant recent announcement here is McKesson’s National Drug Code approval for a Neulasta biosimilar, which ties directly into the thesis around higher value specialty and oncology offerings. This step fits with McKesson’s broader push into more complex pharmaceuticals and services that could support its role in an increasingly complex supply chain and help offset pressure from lower margin generics over time.
Yet investors should be aware that increasing regulatory scrutiny of drug pricing could still…
Read the full narrative on McKesson (it’s free!)
McKesson’s narrative projects $478.8 billion revenue and $5.3 billion earnings by 2028.
Uncover how McKesson’s forecasts yield a $995.27 fair value, a 6% upside to its current price.
Five members of the Simply Wall St Community place McKesson’s fair value between US$665 and about US$1,482, showing a wide spread of expectations. Against that backdrop, the push into higher value biosimilars and specialty services may shape how you weigh McKesson’s growth potential versus ongoing pressure on drug pricing and healthcare costs.
Explore 5 other fair value estimates on McKesson – why the stock might be worth as much as 57% more than the current price!